Longevity Health's Net Loss Widens to $10.9M Amid AxoBio Integration

TL;DR

**Longevity Health's widening $10.9 million net loss and complex debt structure make it a risky bet, despite strategic acquisitions.**

AI Summary

Longevity Health Holdings, Inc. (XAGEW) filed a 10-K/A on June 17, 2025, primarily to amend its financial statements for the fiscal year ended December 31, 2024. The company reported a net loss of $10.9 million for the year ended December 31, 2024, a significant increase from the $4.7 million net loss in the prior year, indicating worsening financial performance. Revenue details were not explicitly provided in the excerpt, but the increased net loss suggests ongoing operational challenges or substantial expenses. Key business changes include the acquisition of Axolotl Biologix, LLC (AxoBio) on August 9, 2023, which involved issuing 1,000 shares of Series A Preferred Stock and assuming a $1.5 million U.S. Small Business Administration loan. The company also engaged in a private placement of convertible notes totaling $2.5 million on December 23, 2024, and issued additional convertible notes in January 2022. Risks include the valuation of Level 3 fair value inputs, particularly for the forward purchase agreement, and the potential impact of the $1.5 million SBA loan assumed from AxoBio. The strategic outlook appears focused on integrating acquisitions like AxoBio and managing its debt structure, including the $2.5 million in new convertible notes.

Why It Matters

This 10-K/A reveals Longevity Health Holdings' deepening financial struggles, with a net loss of $10.9 million in 2024, which is critical for investors assessing the company's viability. The acquisition of Axolotl Biologix, LLC, while strategic, has introduced a $1.5 million SBA loan and complex valuation challenges for Level 3 fair value inputs, impacting the company's balance sheet. Competitively, Longevity Health is attempting to expand its market presence through M&A, but its increasing losses could hinder its ability to compete with more financially stable players in the health and biotech sectors. Employees and customers of AxoBio might face uncertainty if Longevity Health's financial health continues to deteriorate, potentially affecting product development and service delivery.

Risk Assessment

Risk Level: high — The company reported a significant net loss of $10.9 million for the year ended December 31, 2024, nearly tripling the $4.7 million loss from the prior year, indicating severe financial deterioration. The reliance on Level 3 fair value inputs for instruments like the forward purchase agreement, which are inherently difficult to value, introduces substantial uncertainty and potential volatility in financial reporting. Additionally, the assumption of a $1.5 million U.S. Small Business Administration loan from AxoBio and the issuance of $2.5 million in new convertible notes on December 23, 2024, increase the company's debt burden and financial leverage.

Analyst Insight

Investors should exercise extreme caution and consider divesting from XAGEW given the escalating net losses and increased debt burden. Prospective investors should avoid initiating positions until there is clear evidence of improved financial performance and a more stable capital structure, as the current trajectory suggests significant operational challenges.

Key Numbers

• $10.9M — Net Loss (Increased from $4.7M in 2023, indicating worsening financial performance for Longevity Health Holdings, Inc. in 2024.)
• $1.5M — SBA Loan (Assumed from Axolotl Biologix, LLC acquisition, adding to Longevity Health's debt burden.)
• $2.5M — Convertible Notes (Issued in a private placement on December 23, 2024, increasing the company's financial leverage.)
• 1,000 — Series A Preferred Stock Shares (Issued as part of the Axolotl Biologix, LLC acquisition on August 9, 2023.)

Key Players & Entities

• Longevity Health Holdings, Inc. (company) — filer of the 10-K/A
• Axolotl Biologix, LLC (company) — acquired entity
• U.S. Small Business Administration (regulator) — loan provider
• $10.9 million (dollar_amount) — net loss for 2024
• $4.7 million (dollar_amount) — net loss for 2023
• $1.5 million (dollar_amount) — SBA loan assumed from AxoBio
• $2.5 million (dollar_amount) — convertible notes issued in December 2024
• December 31, 2024 (date) — fiscal year end
• August 9, 2023 (date) — AxoBio acquisition date
• December 23, 2024 (date) — date of private placement

FAQ

Risk Factors

• Valuation of Level 3 Fair Value Inputs [medium — financial]: The company's financial statements rely on Level 3 fair value inputs, particularly for the forward purchase agreement. These inputs are unobservable and require significant judgment, increasing the risk of valuation inaccuracies. The valuation technique used, such as an option pricing model, is sensitive to changes in inputs like debt rates, potentially impacting reported asset and liability values.
• Assumed SBA Loan Obligation [medium — financial]: Longevity Health Holdings assumed a $1.5 million U.S. Small Business Administration loan as part of the Axolotl Biologix, LLC acquisition. This debt adds to the company's financial leverage and repayment obligations, potentially straining cash flow, especially given the reported net loss for the fiscal year.
• Increased Convertible Notes Indebtedness [medium — financial]: The company issued $2.5 million in convertible notes through a private placement on December 23, 2024. This issuance, along with previously issued convertible notes, increases the company's debt burden and introduces potential dilution for common shareholders upon conversion.
• Integration of Axolotl Biologix Acquisition [medium — operational]: The acquisition of Axolotl Biologix, LLC (AxoBio) on August 9, 2023, requires successful integration to realize expected synergies. Challenges in integrating operations, technology, or personnel could hinder the expected benefits and impact overall financial performance.

Industry Context

Longevity Health Holdings operates in the industrial applications and services sector, specifically categorized under SOAP, DETERGENT, CLEANING PREPARATIONS, PERFUMES, COSMETICS. This sector is characterized by consumer product demand, innovation in formulations, and competitive pricing pressures. Companies often focus on brand building, distribution networks, and regulatory compliance for product safety.

Regulatory Implications

As a company in the chemical and consumer goods sector, Longevity Health Holdings is subject to regulations concerning product safety, environmental impact, and manufacturing standards. Compliance with these regulations is crucial to avoid penalties and maintain market access. The filing of an amended 10-K/A suggests a need for accurate financial reporting to meet SEC requirements.

What Investors Should Do

1. Monitor integration progress of Axolotl Biologix, LLC.
2. Analyze the impact of increased debt levels.
3. Scrutinize Level 3 fair value inputs.

Key Dates

• 2024-12-23: Private Placement of Convertible Notes — The company raised $2.5 million, increasing its financial leverage and potentially impacting future equity dilution.
• 2023-08-09: Acquisition of Axolotl Biologix, LLC — This strategic acquisition involved issuing 1,000 shares of Series A Preferred Stock and assuming a $1.5 million SBA loan, impacting the company's asset base and debt structure.
• 2024-12-31: Fiscal Year End — The company reported a net loss of $10.9 million for the year, a significant increase from the prior year, indicating deteriorating financial performance.

Glossary

10-K/A

An amended annual report filed with the SEC to correct or supplement information previously filed in a 10-K report. (This filing indicates Longevity Health Holdings is amending its 2024 annual report, primarily to revise financial statements.)

Level 3 Fair Value Inputs

Unobservable inputs used in fair value measurements that are based on the company's own assumptions and models. (These inputs are critical for valuing certain assets and liabilities, like the forward purchase agreement, and carry a higher degree of uncertainty.)

Convertible Notes

Debt instruments that can be converted into a predetermined amount of the issuer's equity at the option of the holder. (The issuance of $2.5 million in convertible notes increases the company's debt and introduces potential future equity dilution.)

Series A Preferred Stock

A class of preferred stock that has priority over common stock in dividend payments and asset distribution in case of liquidation. (1,000 shares were issued as part of the Axolotl Biologix acquisition, representing a specific class of equity issued.)

U.S. Small Business Administration Loan

A loan guaranteed by the SBA, often provided through private lenders, to support small businesses. (The company assumed a $1.5 million SBA loan, adding to its debt obligations.)

Year-Over-Year Comparison

The amended 10-K/A for the fiscal year ended December 31, 2024, reveals a significant deterioration in financial performance compared to the prior year. The net loss widened to $10.9 million from $4.7 million in 2023, indicating increased operational challenges or expenses. While specific revenue figures are not detailed, the increased loss suggests revenue may not have kept pace with costs. New risks have emerged, including the assumption of a $1.5 million SBA loan and the issuance of $2.5 million in convertible notes, increasing the company's financial leverage.

Filing Details

This Form 10-K/A (Form 10-K/A) was filed with the SEC on June 17, 2025 regarding Longevity Health Holdings, Inc. (XAGEW).

View full filing on EDGAR

View Full Filing

View this 10-K/A filing on SEC EDGAR